Aktis Oncology (NASDAQ:AKTS) Shares Up 6.6% After Analyst Upgrade

Aktis Oncology (NASDAQ:AKTS)’s share price was up 6.6% during trading on Tuesday after Raymond James Financial upgraded the stock to a strong-buy rating. The company traded as high as $22.12 and last traded at $22.0490. Approximately 46,609 shares traded hands during trading, a decline of 84% from the average daily volume of 297,901 shares. The stock had previously closed at $20.69.

AKTS has been the subject of a number of other research reports. William Blair started coverage on shares of Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating for the company. HC Wainwright increased their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Finally, Weiss Ratings cut Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Aktis Oncology Stock Up 4.0%

The firm’s 50 day moving average price is $19.54.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The firm had revenue of $1.87 million during the quarter. On average, equities analysts predict that Aktis Oncology will post -1.62 EPS for the current year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.